A leading cybersecurity platform purpose-built for small and medium-sized enterprises (SMEs), today announced it has received a US $100 Million funding from Global Private Equity Partners.
The new investment will reinforce Company's market dominance and accelerate its mission.
Global Private Equity Partners provided a US $300 Million 10-year Term Loan with no financial maintenance covenants, the client is Media and Entertainment Firm with offices in the US, Europe and Middle East, including Dubai.
Global Private Equity Partners provided a US $650 Million 8-year Term Loan with no financial maintenance covenants, the client is Building Supplies manufacturer and importer with offices in Europe and Middle East, including Dubai. The Loan is used for expansion.
GLOBAL PRIVATE EQUITY PARTNERS provided a US $245 Million credit line to a company unlocking transfer RNA (tRNA) biology and pioneering tRNA medicines to regulate the protein universe and resolve disease, GLOBAL PRIVATE EQUITY PARTNERS has 33% shareholding position in the company
A Global Leader in developing Artificial Intelligence (AI) and technology to combat life-threatening neurovascular, cardiac and vascular diseases, today announced a US$250 Million in funding provided by Global Private Equity Partners.
European based developer of Artificial Intelligence (AI) and technology solutions for life-threatening neurovascular, cardiac and vascular diseases, received a US $290 Million funding from Global Private Equity Partners.
GLOBAL PRIVATE EQUITY PARTNERS Arranges US $455 Million Financing for Solar Power Equipment Manufacturer.
The Solar Power Equipment Manufacturer plans to expand their solar power equipment manufacturing facility and to expand within the Middle East Countries.
GLOBAL PRIVATE EQUITY PARTNERS have established a consumer tech investment fund of US $1 Billion, GLOBAL PRIVATE EQUITY PARTNERS is the sole owner of the fund.
Global Private Equity Partners has partnered with one the world's leading defense technology companies for space-based radio frequency (RF) data and analytics in exchange of 33% shareholding position for a US $125 Capital injection.
European-based biotechnology company concentrating on vision-restoring engineered cell-based therapeutics and in vivo reprogramming, received a US $300 Million funding from Global Private Equity Partners.
Global Private Equity Partners is a 51% shareholder in the company.
European-based biotechnology company concentrating on vision-restoring engineered cell-based therapeutics and in vivo reprogramming, received a US $3000 Million funding from Global Private Equity Partners.
Global Private Equity Partners is a 51% shareholder in the company.